737 related articles for article (PubMed ID: 17659339)
21. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
[TBL] [Abstract][Full Text] [Related]
22. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
23. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents.
Sánchez-Pérez T; Ortiz-Ferrón G; López-Rivas A
Cell Death Differ; 2010 May; 17(5):883-94. PubMed ID: 19942932
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
[TBL] [Abstract][Full Text] [Related]
26. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
[TBL] [Abstract][Full Text] [Related]
27. Withaferin A sensitizes TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Lee TJ; Um HJ; Min do S; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2009 Jun; 46(12):1639-49. PubMed ID: 19345731
[TBL] [Abstract][Full Text] [Related]
28. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.
Papageorgiou A; Lashinger L; Millikan R; Grossman HB; Benedict W; Dinney CP; McConkey DJ
Cancer Res; 2004 Dec; 64(24):8973-9. PubMed ID: 15604261
[TBL] [Abstract][Full Text] [Related]
29. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
[TBL] [Abstract][Full Text] [Related]
30. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
[TBL] [Abstract][Full Text] [Related]
31. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation.
Kim YH; Lee YJ
J Cell Biochem; 2007 Mar; 100(4):998-1009. PubMed ID: 17031854
[TBL] [Abstract][Full Text] [Related]
32. Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins.
Lee SJ; Noh HJ; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
Int J Oncol; 2011 Feb; 38(2):485-92. PubMed ID: 21170508
[TBL] [Abstract][Full Text] [Related]
33. The expression of TRAIL and its receptors in gastric cancer and the apoptotic effect of rh-TRAIL on SGC7901 cells.
Hu JK; Yang K; Li CM; Zhang B; Chen ZX; Chen XZ; Chen JP
Oncol Rep; 2009 Mar; 21(3):681-8. PubMed ID: 19212626
[TBL] [Abstract][Full Text] [Related]
34. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L).
Guseva NV; Rokhlin OW; Taghiyev AF; Cohen MB
Breast Cancer Res Treat; 2008 Feb; 107(3):349-57. PubMed ID: 17453339
[TBL] [Abstract][Full Text] [Related]
35. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells.
Palacios C; Yerbes R; López-Rivas A
Cancer Res; 2006 Sep; 66(17):8858-69. PubMed ID: 16951203
[TBL] [Abstract][Full Text] [Related]
36. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
37. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.
Siegmund D; Klose S; Zhou D; Baumann B; Röder C; Kalthoff H; Wajant H; Trauzold A
Cell Signal; 2007 Jun; 19(6):1172-84. PubMed ID: 17291719
[TBL] [Abstract][Full Text] [Related]
38. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Thorpe JA; Christian PA; Schwarze SR
Prostate; 2008 Feb; 68(2):200-9. PubMed ID: 18076022
[TBL] [Abstract][Full Text] [Related]
40. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
